Tailoring the Release of Paclitaxel from Electrospun Nonwovens
Authors:
- Bartosz JaroszewskiBJBartosz Jaroszewski
- Monika Musiał-KulikMMMonika Musiał-Kulik
- Ryszard SmolarczykRSRyszard Smolarczyk
- Tomasz CichońTCTomasz Cichoń
- Alina DrzyzgaADAlina Drzyzga
- Ewelina PilnyEPEwelina Pilny
- Mateusz StojkoMateusz Stojko
- Jakub WłodarczykJWJakub Włodarczyk
- Joanna JaworskaJJJoanna Jaworska
- Anna KapsAKAnna Kaps
- Piotr PaduszyńskiPPPiotr Paduszyński
- Marzena Jaworska-KikMJMarzena Jaworska-Kik
Open Access
- 28 November 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11540
Abstract
Implantable drug delivery devices may enhance therapeutic efficacy by allowing localized drug release, and they may overcome the drawbacks of conventional systemic treatment. Electrospun nanofibers are promising drug delivery systems due to their high surface-to-volume ratio, porosity, and easy drug encapsulation. However, controlled and sustained drug release is required to improve therapeutic efficacy and reduce toxicity. Also, the ability to tailor the release drug dose would be a useful tool for providing an optimal and individualized approach for the treatment. Therefore, the aim of the study was to analyze the possibility to tailor the release of paclitaxel (PTX) from poly(D,L-lactide-co-glycolide) (PDLGA) electrospun nonwovens by modifying the comonomer molar ratio. For this purpose, three kinds of polymers were compared with lactidyl-to-glycolidyl comonomer ratios of 86:14, 70:30, and 48:52. Also, nonwovens obtained from a blend of PDLGA and PVA were used to analyze the effect of the addition of the hydrophilic polymer on degradation and, thus, the release rate. The comprehensive analysis of the developed nonwovens was conducted through an evaluation of the morphology, in vitro degradation, and drug release process, as well as cytotoxicity. It has been observed that all kinds of the developed PDLGA nonwovens provide an extended-release profile but with different release rates, which depend on the comonomer unit ratio and molar mass of the copolymer. Moreover, the increase in hydrophilicity caused by PVA sufficiently accelerates PTX release. The biological activity of released PTX was confirmed under in vitro and in vivo conditions against 4T1 mouse mammary carcinoma. The results of the study enabled us to gain insight into the influence of polymer choice on PTX release from PDLGA ES implants, which may be helpful in their easier translation into the clinic and for better adjustment of the PTX dose for individual treatment.Keywords
Funding Information
- Narodowe Centrum Nauki (2021/41/B/NZ7/01246)
This publication has 51 references indexed in Scilit:
- Encapsulation of Drug‐Loaded Graphene Oxide‐Based Nanocarrier into Electrospun Pullulan Nanofibers for Potential Local Chemotherapy of Breast CancerMacromolecular Chemistry and Physics, 2021
- Emerging Technologies for Local Cancer TreatmentAdvanced Therapeutics, 2020
- Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticlesJournal of Pharmaceutical Investigation, 2019
- Paclitaxel‐Loaded Polylactide/Polyethylene Glycol Fibers with Long‐Term Antitumor Activity as a Potential Drug Carrier for Local ChemotherapyMacromolecular Bioscience, 2018
- Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration ApplicationsAdvanced Healthcare Materials, 2017
- Recent applications of PLGA based nanostructures in drug deliveryColloids and Surfaces B: Biointerfaces, 2017
- Injectable formulations of poly(lactic acid) and its copolymers in clinical useAdvanced Drug Delivery Reviews, 2016
- Effect of copolymer ratio on hydrolytic degradation of poly(lactide-co-glycolide) from drug eluting coronary stentsChemical Engineering Research and Design, 2011
- Managing taxane toxicitiesSupportive Care in Cancer, 2003
- A simple equation for the description of solute release. III. Coupling of diffusion and relaxationInternational Journal of Pharmaceutics, 1989